ScreenPoint Medical deploys Transpara® Breast AI at Johns Hopkins to improve cancer detection

ScreenPoint Medical announced that its cutting-edge product Transpara Breast AI is available to improve cancer detection for patients at the Johns Hopkins Breast Cancer Screening Center. Transpara helps radiologists read 2D and 3D mammograms, providing a “second pair of eyes” that helps detect cancers earlier and reduce recall rates.

The Johns Hopkins Kimmel Cancer Center was one of the first to be recognized by the National Cancer Institute as a “Center of Excellence.” Across Johns Hopkins , the Breast Imaging Services team performs more than 77,000 mammograms and 5,000 procedures each year. The choice to use Transpara was made after an in-depth analysis of the software's evidence, effectiveness and performance on selected cases. The Johns Hopkins Breast Imaging team evaluated Transpara, trusted by key opinion leaders in breast imaging worldwide, in an in-depth competitive comparison.

ScreenPoint's Customer Success team worked closely with Johns Hopkins clinical and IT teams to install Transpara Breast AI to support patient care across 7 sites. Transpara was chosen to improve screening workflow, decision confidence and assessment of breast cancer diagnosis.

“We are delighted that Johns Hopkins has trusted ScreenPoint Medical in its fight against cancer. Transpara is the most clinically validated breast AI on the market, proven to improve radiologists' ability to detect breast cancer as early as possible. As part of the ScreenPoint experience, once a customer chooses to use Transpara, we want to create those benefits in weeks, not months, said Nicki Bryan, vice president of sales at ScreenPoint Medical. We are also very grateful to the professionals on the Johns Hopkins team who collaborated so effectively to ensure a smooth and seamless technical transition! »

With the integration of Johns Hopkins , the growing use of Transpara in the Northeast will now benefit radiologists and patients in more than 50 locations across 5 states (NY, NJ, PA, MD, VA) and the District of Columbia .

Transpara is FDA cleared and approved by the European MDR for use with 2D and 3D mammograms from several manufacturers. Used by hundreds of leading centers in more than 30 countries, Transpara is designed to work in parallel with radiologists. Studies show that Transpara helps detect up to 45% of interval cancers earlier, while helping to reduce workload and optimize workflow.